RRC ID 42891
Author Enosawa S, Miyashita T, Saito T, Omasa T, Matsumura T.
Title The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model.
Journal Cell Transplant
Abstract We developed a bioartificial liver (BAL) containing human hepatoblastoma cell line, HepG2, with the addition of ammonia removal activity by transfecting a glutamine synthetase (GS) gene and estimated the efficacy using pigs with ischemic liver failure. GS-HepG2 cells showed 15% ammonia removal activity of porcine hepatocytes, while unmodified HepG2 had no such activity. The established GS-HepG2 cells were grown in a circulatory flow bioreactor to 3.5-4.1 x 10(9) cells. Survival time of the animals treated with GS-HepG2 BAL was significantly prolonged compared to the cell-free control (14.52 +/- 5.24 h vs. 8.53 +/- 2.52 h) and the group treated with the BAL consisting of unmodified wild-type HepG2 (9.58 +/- 4.52 h). Comparison showed the cell-containing BAL groups to have significantly fewer incidences of increased brain pressure. Thus, the GS-HepG2 BAL treatment resulted in a significant improvement of survival time and pathological parameters in pigs with ischemic liver failure.
Volume 15(10)
Pages 873-80
Published 2006-1-1
DOI 10.3727/000000006783981350
PMID 17299991
MeSH Animals Bioreactors Cell Culture Techniques Cell Line, Tumor Cell Transplantation Cricetinae Disease Models, Animal Female Glutamate-Ammonia Ligase / genetics Glutamate-Ammonia Ligase / metabolism* Humans Liver Failure / metabolism Liver Failure / mortality Liver Failure / therapy* Liver, Artificial* Male Models, Biological Survival Rate Swine Transfection
IF 3.341
Times Cited 23
Human and Animal Cells Hep G2